PTIRelated Companies
NSE
BSE
NEW DELHI: Shares of Lupin climbed 2 per cent in Tuesday's trade after the drug maker received a USFDA approval for a generic drug used to treat Wilson’s disease, Cystinuria, and severe active rheumatoid arthritis patients.
Following the development, the stock rose 2.48 per cent to hit a high of Rs 914 on BSE.
The company told stock exchanges that it received approval for its Penicillamine Tablets USP, 250 mg, from the us drug regulator to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty.
"The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly," Lupin told BSE.
Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Depen had an annual sales of approximately $4 million in the US, as per IQVIA MAT September.
Following the development, the stock rose 2.48 per cent to hit a high of Rs 914 on BSE.
The company told stock exchanges that it received approval for its Penicillamine Tablets USP, 250 mg, from the us drug regulator to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty.
"The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly," Lupin told BSE.
Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Depen had an annual sales of approximately $4 million in the US, as per IQVIA MAT September.
Download The Economic Times News App to get Daily Market Updates & Live Business News.
